CA2331878A1 - Pyrazoles a substitution 1,5-diaryle comme inhibiteurs de la proteine p38 kinase - Google Patents
Pyrazoles a substitution 1,5-diaryle comme inhibiteurs de la proteine p38 kinase Download PDFInfo
- Publication number
- CA2331878A1 CA2331878A1 CA002331878A CA2331878A CA2331878A1 CA 2331878 A1 CA2331878 A1 CA 2331878A1 CA 002331878 A CA002331878 A CA 002331878A CA 2331878 A CA2331878 A CA 2331878A CA 2331878 A1 CA2331878 A1 CA 2331878A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrocarbyl
- aryl
- group
- hydrido
- hydrocarbyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Cette invention, qui a trait à des composés de pyrazole à substitution 1,5-diaryle, représentés par la formule (I) dans laquelle A représente =N ou =CH-, concerne également un sel de ces composés, acceptable du point de vue pharmaceutique. Ces composés, entre autres effets, inhibent l'activité de la protéine-kinase associée aux membranes, en l'occurrence la protéine p38. Elle porte également sur des procédés de préparation de ces composés ainsi que sur l'utilisation qui est faite de l'un deux pour traiter un mammifère atteint d'une maladie liée à la p38 kinase ou au facteur de nécrose tumorale.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8549498P | 1998-05-14 | 1998-05-14 | |
US60/085,494 | 1998-05-14 | ||
PCT/US1999/007036 WO1999058523A1 (fr) | 1998-05-14 | 1999-05-12 | PYRAZOLES A SUBSTITUTION 1,5-DIARYLE COMME INHIBITEURS DE LA PROTEINE p38 KINASE |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2331878A1 true CA2331878A1 (fr) | 1999-11-18 |
Family
ID=22191985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002331878A Abandoned CA2331878A1 (fr) | 1998-05-14 | 1999-05-12 | Pyrazoles a substitution 1,5-diaryle comme inhibiteurs de la proteine p38 kinase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1077971A1 (fr) |
JP (1) | JP2002514640A (fr) |
AU (1) | AU3859999A (fr) |
CA (1) | CA2331878A1 (fr) |
WO (1) | WO1999058523A1 (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
WO1998056377A1 (fr) * | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | Nouveaux composes de pyrazole et de pyrazoline substitues |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
JP4632544B2 (ja) * | 1998-12-25 | 2011-02-16 | あすか製薬株式会社 | アミノピラゾール誘導体 |
US6667325B1 (en) | 1999-06-03 | 2003-12-23 | Teikoku Hormone Mfg. Co., Ltd. | Substituted pyrazole compounds |
US7122666B2 (en) | 1999-07-21 | 2006-10-17 | Sankyo Company, Limited | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
AU1781601A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
US6569885B1 (en) | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6403629B2 (en) * | 2000-05-02 | 2002-06-11 | J.B. Chemical And Pharmaceuticals Limited | Heterocyclic compounds for therapeutic use |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
ES2243579T3 (es) | 2000-12-15 | 2005-12-01 | Glaxo Group Ltd | Derivados de pirazolopirideno. |
DE60112609T2 (de) | 2000-12-15 | 2006-01-19 | Glaxo Group Ltd., Greenford | Pyrazolopyridine |
GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
ATE274515T1 (de) | 2001-03-08 | 2004-09-15 | Smithkline Beecham Corp | Pyrazolopyridinderivate |
GB2373245A (en) * | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
US7034030B2 (en) | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
WO2002083672A1 (fr) | 2001-04-10 | 2002-10-24 | Smithkline Beecham Corporation | Composes de pyrazolopyridine antiviraux |
DE60204452T2 (de) | 2001-04-27 | 2005-12-15 | Smithkline Beecham Corp. | Pyrazolo[1,5a]Pyridinderivate |
US6878729B2 (en) * | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
EP1401836B1 (fr) | 2001-06-21 | 2006-08-23 | SmithKline Beecham Corporation | Derives d'imidazo¬1,2-a|pyridine destines a la prevention et au traitement d'infections au virus de l'herpes |
ATE309239T1 (de) * | 2001-08-30 | 2005-11-15 | Hoffmann La Roche | Aminopyrrol verbindungen als entzündungshemmende wirkstoffe |
US7057049B2 (en) | 2001-09-25 | 2006-06-06 | Pharmacia Corporation | Process for making substituted pyrazoles |
KR100697482B1 (ko) | 2001-09-25 | 2007-03-20 | 파마시아 코포레이션 | 치환된 피라졸의 제조 방법 |
DE60211539T2 (de) | 2001-10-05 | 2006-09-21 | Smithkline Beecham Corp. | Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion |
GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0127929D0 (en) | 2001-11-21 | 2002-01-16 | Celltech R&D Ltd | Chemical compounds |
DE60222465T2 (de) * | 2001-12-11 | 2008-06-05 | Smithkline Beecham Corp. | Pyrazolopyridin-derivate als antiherpesmittel |
AU2002353147A1 (en) * | 2001-12-13 | 2003-06-30 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2004004725A2 (fr) | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Nouvelles compositions pharmaceutiques a base de nouveaux anticholinergiques et d'inhibiteurs de la kinase p38 |
ATE323702T1 (de) | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
WO2004033454A1 (fr) | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Composes therapeutiques a base de derives de pyrazolopyridine |
ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
EP1591443B1 (fr) | 2003-02-07 | 2010-08-25 | Daiichi Sankyo Company, Limited | Derive de pyrazole |
EP1620108B1 (fr) | 2003-05-01 | 2012-06-06 | Bristol-Myers Squibb Company | Composes de pyrazole-amines utiles en tant qu'inhibiteurs de kinases |
GB0402518D0 (en) | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
GB0417910D0 (en) * | 2004-08-11 | 2004-09-15 | Novartis Ag | Organic compounds |
AP2326A (en) | 2004-08-12 | 2011-11-24 | Pfizer | Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors. |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EP1992344A1 (fr) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3 |
US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2013059677A1 (fr) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Composés qui modulent le calcium intracellulaire |
SG11201605559VA (en) * | 2014-01-06 | 2016-08-30 | Algomedix Inc | Trpa1 modulators |
EP3481808A4 (fr) * | 2016-07-06 | 2020-07-15 | Algomedix, Inc. | Antagonistes trpa1 pour le traitement du syndrome de l' il sec, de la douleur oculaire et de l'inflammation |
CA3209491A1 (fr) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire |
CN114773262B (zh) * | 2022-05-19 | 2024-05-07 | 兄弟科技股份有限公司 | 2-氰基-4-吡啶羧酸甲酯的合成方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833779A (en) * | 1956-10-29 | 1958-05-06 | American Cyanamid Co | Substituted pyrazoles |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
WO1998056377A1 (fr) * | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | Nouveaux composes de pyrazole et de pyrazoline substitues |
-
1999
- 1999-05-12 WO PCT/US1999/007036 patent/WO1999058523A1/fr active Application Filing
- 1999-05-12 CA CA002331878A patent/CA2331878A1/fr not_active Abandoned
- 1999-05-12 AU AU38599/99A patent/AU3859999A/en not_active Abandoned
- 1999-05-12 EP EP99921363A patent/EP1077971A1/fr not_active Withdrawn
- 1999-05-12 JP JP2000548327A patent/JP2002514640A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2002514640A (ja) | 2002-05-21 |
WO1999058523A1 (fr) | 1999-11-18 |
EP1077971A1 (fr) | 2001-02-28 |
AU3859999A (en) | 1999-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6509361B1 (en) | 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors | |
CA2331878A1 (fr) | Pyrazoles a substitution 1,5-diaryle comme inhibiteurs de la proteine p38 kinase | |
AU755498B2 (en) | 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | |
US6579873B2 (en) | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | |
US6503930B1 (en) | Pyrazole derivatives as p38 kinase inhibitors | |
CA2469821C (fr) | Modulateurs triazole substitues par heteroaryle du recepteur metabotropique 5 du glutamate | |
AU2004226165C1 (en) | Pyrimidin-4-one derivatives and their use as p38 kinase modulators | |
RU2196139C2 (ru) | 1,4,5-тризамещенные производные имидазола, способы их получения и фармацевтическая композиция на их основе | |
CN100358888C (zh) | 作为因子Xa抑制剂的新的胍模拟物 | |
JP2001526230A (ja) | ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用 | |
AU2005321946A1 (en) | Enzyme modulators and treatments | |
CA2351725A1 (fr) | Pyrazoles substitues utilises comme inhibiteurs de la kinase p38 | |
WO2004089303A2 (fr) | Modulateurs au pyrazole a substitution diaryle du recepteur-5 de glutamate metabotropique | |
WO2009038847A1 (fr) | N-(2-(hétaryl)aryl)arylsulfonamides et n-(2-(hétaryl)hétaryl)arylsulfonamides | |
EP1000055A1 (fr) | PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE p38 KINASE | |
US7268151B2 (en) | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 | |
JP2002528506A (ja) | ピリジン−4−イルまたはピリミジン−4−イル置換ピラジン | |
CZ408999A3 (cs) | 3(5)-Heteroaryl substituované pyrazoly jako inhibitory kinázy p38 | |
MXPA99010733A (en) | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |